Publications by authors named "A Kaldun Kaldun Nossuli"
Article Synopsis
- - This study examined the effects of daprodustat, a new oral medication for anemia in chronic kidney disease, focusing on its impact on hemoglobin levels and safety compared to traditional treatments like erythropoietin (rhEPO).
- - Participants (216) on hemodialysis were switched from rhEPO to daprodustat at varying doses and their hemoglobin levels were monitored over 24 weeks, with initial results showing significant hemoglobin increases in the daprodustat group during the first 4 weeks.
- - While both treatment groups showed similar hemoglobin levels after 24 weeks, daprodustat's safety profile was consistent with patients on hemodialysis, suggesting it could be a viable
Patients on dialysis require phosphorus binders to prevent hyperphosphatemia and are iron deficient. We studied ferric citrate as a phosphorus binder and iron source. In this sequential, randomized trial, 441 subjects on dialysis were randomized to ferric citrate or active control in a 52-week active control period followed by a 4-week placebo control period, in which subjects on ferric citrate who completed the active control period were rerandomized to ferric citrate or placebo.
View Article and Find Full Text PDF